Medical Care Technologies (OTC Pink:MDCE) Positions Itself in the Multi-Billion Dollar AI Dermatology Market With Google-Backed Melanoma Detection Technology

Rhea-AI Summary

Medical Care Technologies (OTC Pink: MDCE) announced on December 8, 2025 that it has integrated Derm Foundation, a Google-backed pretrained dermatology imaging model, into its soon-to-launch AI wound and skin monitoring mobile platform.

The integration provides melanoma risk classification, chronic-wound progress tracking, data-efficient classification for conditions like psoriasis and dermatitis, automated image-quality checks, and HTTPS API integration for rapid mobile deployment. The company positions the app to enable earlier melanoma detection and reduce preventable hospitalizations by detecting infection risk and wound deterioration from smartphone images.

Company claims note melanoma early-detection survival can reach up to 99% and cite chronic wounds affecting 50 million+ people globally; the app targets rural, underserved and telehealth use cases.

News Market Reaction

%

1 alert

% News Effect

On the day this news was published, MDCE declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Early detection survival: up to 99% Chronic wound prevalence: 50 million+ people

2 metrics

Early detection survival up to 99% Melanoma early-detection survival rate cited in article

Chronic wound prevalence 50 million+ people Global chronic wound impact mentioned in article

Market Reality Check

Price: $0.0003 Vol: Volume 62,888,866 is 1.28...

normal vol

$0.0003 Last Close

Volume Volume 62,888,866 is 1.28x the 20-day average of 49,205,049, indicating elevated trading activity. normal

Technical Price at 0.0004 is trading above the 200-day MA of 0.

Peers on Argus

MDCE fell 16.67% while close peers were mixed: YUKA down 5.45%, BBTT up 1.52%, a...

MDCE fell 16.67% while close peers were mixed: YUKA down 5.45%, BBTT up 1.52%, and others flat. Moves do not indicate a broad sector shift.

Historical Context

5 past events · Latest: Dec 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 09	Partnership and structure	Positive	-14.3%	Share structure stabilization and new tech partnership highlighted as growth drivers.
Dec 08	AI dermatology integration	Positive	+0.0%	Integration of Google-backed Derm Foundation into AI wound and skin app.
Dec 05	Reg A closure	Positive	+40.0%	End of Reg A dilution and shift toward product launches and AI innovation.
Dec 04	AI health strategy	Positive	+0.0%	Plan to leverage subsidiaries to support broader AI health app catalog.
Dec 03	Lean AI model	Positive	+0.0%	Description of lean, outsourced AI model and pending patent application.

Pattern Detected

Recent positive corporate and AI updates often met with flat or negative next-day moves, with only the Reg A closure seeing a strong positive reaction.

Recent Company History

Over late November–December 2025, MDCE highlighted a lean AI model, expansion into AI health and wellness apps, and closure of its Reg A offering effective December 6, 2025. AI infrastructure and pre-health screening initiatives, including melanoma and wound-focused tools, were emphasized. Despite this, several ostensibly positive AI and partnership updates on December 3–9 saw flat or negative 24h price reactions, while the Reg A dilution-ending news on December 5 coincided with a 40% gain.

Market Pulse Summary

This announcement highlights MDCE’s integration of a Google-backed dermatology imaging model into it...

Analysis

This announcement highlights MDCE’s integration of a Google-backed dermatology imaging model into its AI wound and skin monitoring app, targeting early detection of melanoma and chronic wound issues. It follows earlier AI infrastructure and product-roadmap updates across health and wellness. With the stock trading well below its 52-week high but above the low, investors may focus on evidence of user adoption, regulatory pathways, and clear milestones toward commercialization of the mobile platform.

Key Terms

melanoma, psoriasis, dermatitis, telehealth, +2 more

6 terms

melanoma medical

"early-warning tools for melanoma, infection risks, and chronic wound"

Melanoma is a serious form of skin cancer that starts in the cells that give skin its color and can grow quickly, often spreading to other parts of the body if not caught early. Investors watch melanoma because its incidence, new treatments, clinical trial results, and regulatory approvals can meaningfully affect drug and device makers’ sales, healthcare costs, and insurer liabilities—similar to how a major product success or failure moves value in other industries.

psoriasis medical

"Data-efficient skin-disease classification including:PsoriasisDermatitisOther"

Psoriasis is a chronic skin condition where the body's defenses cause skin cells to build up rapidly, producing red, scaly, and often itchy patches. It matters to investors because it creates a steady market for long-term treatments, devices and services—similar to a recurring customer need—affecting drug development, clinical trial pipelines, pricing, and healthcare spending across pharmaceuticals and medical providers.

dermatitis medical

"Data-efficient skin-disease classification including:PsoriasisDermatitisOther"

Dermatitis is inflammation of the skin that causes redness, itching, swelling or blisters—think of it like the skin reacting badly to an irritant, allergy or moisture imbalance. For investors, dermatitis matters because its prevalence drives demand for prescription drugs, over‑the‑counter treatments, skincare products and related clinical trials or regulatory approvals, all of which can affect sales, research spending and the valuation of healthcare and consumer goods companies.

telehealth medical

"Empower users in rural and underserved communitiesSupport telehealth and caregiver"

Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.

API technical

"Full integration for mobile apps via HTTPS "predict" API endpoints"

An API, or Application Programming Interface, is a set of rules that allows different software programs to communicate and work together smoothly, much like a waiter translating your order into the kitchen and then bringing your meal back. For investors, APIs are important because they enable real-time access to financial data, trading systems, and other digital services, making it easier to make informed decisions quickly and efficiently.

HTTPS technical

"Full integration for mobile apps via HTTPS "predict" API endpoints"

HTTPS is the secure version of a website address that encrypts information sent between your browser and a site, like sending a sealed envelope instead of a postcard so others can’t read it if intercepted. For investors, HTTPS matters because it protects customer data, reduces risk of fraud and regulatory trouble, and boosts user trust and search visibility—factors that can influence traffic, sales and company reputation.

AI-generated analysis. Not financial advice.

MESA, ARIZONA / ACCESS Newswire / December 8, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is thrilled to announce a major technology advancement in the development of its soon-to-launch AI wound and skin monitoring platform. The Company has strategically aligned with Derm Foundation, a Google-backed pretrained dermatology imaging model, enabling the app to rapidly evolve into one of the most accessible early-warning tools for melanoma, infection risks, and chronic wound deterioration directly from a smartphone.

Led by CEO Marshall Perkins, MDCE is building a revolutionary solution empowering users to capture wound and skin images safely at home, while AI analyzes and detects subtle-often early and invisible-signs of disease progression.

"We are deploying one of the world's most advanced dermatology AI models into an easy-to-use mobile platform," said Perkins.
"Our mission is to save lives by enabling earlier melanoma detection and reducing preventable hospitalizations from chronic wounds."

Derm Foundation: A High-Power AI Engine Built for Clinical Skin Detection

Derm Foundation technology provides MDCE with:

• Melanoma risk classification - identifying suspicious lesions and alerting users to potential early skin-cancer indicators

• Progress tracking for chronic wounds - enabling sequential imaging to detect stagnation or infection risks

• Data-efficient skin-disease classification including:

  • Psoriasis

  • Dermatitis

  • Other dermatological conditions aligned with clinical screening

• Automated image quality checks - ensuring photos are suitable for reliable AI analysis

• Full integration for mobile apps via HTTPS "predict" API endpoints

By embedding Derm Foundation, MDCE can rapidly scale world-class AI dermatology capabilities into a consumer-first solution without waiting for traditional multi-year model development.

A Global Need for Early Detection - Delivered at Home

Melanoma is the deadliest form of skin cancer - yet early detection can increase survival rate up to 99%.

Chronic wounds, including diabetic ulcers, impact 50 million+ people globally and contribute to billions in avoidable medical costs each year.

MDCE's app is designed to:

• Detect and flag early melanoma suspicion

• Track wound healing trajectories in real time

• Help prevent infections and amputations

• Empower users in rural and underserved communities

• Support telehealth and caregiver coordination

"Dermatological and wound-care intelligence shouldn't only be available inside a hospital," Perkins added.
"We are democratizing access to some of the most critical early-screening tools in modern medicine."

About Medical Care Technologies Inc.

Medical Care Technologies Inc. (OTC Pink: MDCE) is redefining preventive and remote healthcare through AI-empowered imaging solutions. The Company is advancing clinical-aligned tools that give users and caregivers greater independence, safety, and decision-making power from their mobile devices.

Learn more: www.medicalcaretechnologies.com

Safe Harbor Statement

This press release contains forward-looking statements, including statements related to technology development, product capabilities, clinical potential, market opportunity, and future business performance. These statements involve risks and uncertainties that could cause actual results to differ materially. Medical Care Technologies Inc. assumes no obligation to update any forward-looking statements.

Contact:

Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com

SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)

View the original press release on ACCESS Newswire

FAQ

What did Medical Care Technologies (MDCE) announce on December 8, 2025 about Derm Foundation?

MDCE announced it integrated the Google-backed Derm Foundation pretrained dermatology model into its upcoming AI wound and skin monitoring app.

How will MDCE's app use Derm Foundation to detect melanoma and wound issues?

The app will use Derm Foundation for melanoma risk classification, chronic-wound progress tracking, infection-risk alerts, and automated image-quality checks.

Does the MDCE announcement specify regulatory approvals or clinical trial results for the app?

No— the announcement describes technology integration and intended uses but does not cite regulatory approvals or completed clinical trial results.

What clinical benefits does MDCE claim the app may provide for melanoma detection?

MDCE highlights that early melanoma detection can raise survival to up to 99% and that the app aims to flag suspicious lesions for earlier evaluation.

Who are the target users for MDCE's AI wound and skin monitoring platform (MDCE)?

The company targets consumers capturing photos at home, rural and underserved communities, caregivers, and telehealth providers.

How will Derm Foundation be delivered inside MDCE's mobile app?

Derm Foundation will be integrated via HTTPS 'predict' API endpoints to enable in-app image analysis and scaling without multi-year model development.